今日消息！开源力量崛起！傅盛力赞阿里云大模型：超越闭源指日可待

开源力量崛起！傅盛力赞阿里云大模型：超越闭源指日可待

北京，2024年6月16日 - 近日，阿里云发布了其最新开源模型Qwen2-72B，该模型参数规模达到720亿，性能超过了美国最强的开源模型Llama3-70B，也超过了众多国内闭源大模型。这一消息在业界引起了广泛关注，也引发了对开源大模型与闭源大模型未来发展趋势的讨论。

对此，猎豹移动董事长兼CEO、猎户星空董事长傅盛发表了看法。他表示，阿里云发布的Qwen2-72B开源模型能力已经超越了国内绝大多数闭源模型，这表明了开源大模型的巨大潜力。

傅盛认为，开源大模型和闭源大模型各有优劣。闭源大模型拥有强大的资金和技术支持，能够快速迭代更新，但在数据和算法方面存在一定限制。而开源大模型则具有开放透明、易于协作的特点，能够汇聚来自全球各地的开发者和研究人员的力量，不断推动模型的进步。

从长远来看，傅盛认为开源大模型的能力将超越闭源大模型。主要原因在于开源并不是简单的做雷锋，而是结合自己的商业模式，结合能够形成社区的反馈能力的一套战略部署。 开源大模型的社区能够持续贡献新的代码和数据，并对模型进行改进，这将使模型的性能和能力得到不断提升。

此外，开源大模型还具有更强的通用性和可扩展性。 由于代码是公开的，任何人都可以对其进行修改和使用，这使得开源大模型能够更广泛地应用于各种场景。

当然，开源大模型也存在一些挑战。 首先，开源社区的管理和维护需要大量的精力和资源。其次，开源模型的质量和可靠性难以保证。

尽管存在挑战，但傅盛依然对开源大模型的未来发展充满信心。他呼吁更多的企业和开发者加入到开源大模型的社区中，共同推动开源大模型的发展和进步。

以下是傅盛对开源大模型未来发展的几点建议：

• 加强开源社区的建设，提高社区的管理水平和运营效率。
• 建立完善的代码质量和安全机制，确保开源模型的质量和可靠性。
• 探索开源商业模式，为开源大模型的可持续发展提供动力。

随着开源大模型的不断发展，其将对各行各业产生深远的影响。 在未来，开源大模型有望成为人工智能发展的重要引擎，推动人工智能技术取得更大的突破。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.